In the serotherapy column in Table 1 on page 2001, for patient 7, “Alemtuzumab” should read “Thymoglobulin.” The error has been corrected in the published article.
© 2020 by The American Society of Hematology
2020
Skip Nav Destination
ERRATUM|
August 20, 2020
Felber M, Steward CG, Kentouche K, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. Blood Adv. 2020;4(9):1998-2010.
Blood Adv (2020) 4 (16): 3926.
Article history
Submitted:
July 29, 2020
Accepted:
July 29, 2020
